Results of a Multicenter Trial using the BTA Test to Monitor for and Diagnose Recurrent Bladder Cancer

M. F. Sarosdy, Ralph W deVere White, M. S. Soloway, J. Sheinfeld, M. A. Hudson, P. F. Schellhammer, M. V. Jarowenko, G. Adams, B. A. Blumenstein

Research output: Contribution to journalArticle

190 Citations (Scopus)

Abstract

Objectives: We compare the Bard BTA † Bainbridge Diagnotic Sciences, C.R. Bard, Inc., Redmond, WA. (bladder tumor antigen) test to voided cytology studies in patients undergoing surveillance cystoscopy for recurrent bladder cancer. Materials and Methods: A prospective, blinded, multicenter trial was performed. Results: A total of 499 patients underwent 1,014 cystoscopic examinations and tumor was identified in 151. The bladder tumor antigen test was mode sensitive than cytology studies in detecting recurrent cancer (p less than 0.001), being positive in 61 cases versus 25 for cytology. The trial in healthy volunteers and nonurological patients estimates bladder tumor antigen test specificity to be 95.9 percent. Conclusions: The bladder tumor antigen test is a simple, rapid and inexpensive adjunct to cystoscopy, and the results are equivalent or superior to those of voided cytology as performed in this trial.

Original languageEnglish (US)
Pages (from-to)379-384
Number of pages6
JournalThe Journal of Urology
Volume154
Issue number2
DOIs
StatePublished - 1995
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Multicenter Studies
Neoplasm Antigens
Cell Biology
Cystoscopy
Neoplasms
Healthy Volunteers

ASJC Scopus subject areas

  • Urology

Cite this

Sarosdy, M. F., deVere White, R. W., Soloway, M. S., Sheinfeld, J., Hudson, M. A., Schellhammer, P. F., ... Blumenstein, B. A. (1995). Results of a Multicenter Trial using the BTA Test to Monitor for and Diagnose Recurrent Bladder Cancer. The Journal of Urology, 154(2), 379-384. https://doi.org/10.1016/S0022-5347(01)67054-X

Results of a Multicenter Trial using the BTA Test to Monitor for and Diagnose Recurrent Bladder Cancer. / Sarosdy, M. F.; deVere White, Ralph W; Soloway, M. S.; Sheinfeld, J.; Hudson, M. A.; Schellhammer, P. F.; Jarowenko, M. V.; Adams, G.; Blumenstein, B. A.

In: The Journal of Urology, Vol. 154, No. 2, 1995, p. 379-384.

Research output: Contribution to journalArticle

Sarosdy, MF, deVere White, RW, Soloway, MS, Sheinfeld, J, Hudson, MA, Schellhammer, PF, Jarowenko, MV, Adams, G & Blumenstein, BA 1995, 'Results of a Multicenter Trial using the BTA Test to Monitor for and Diagnose Recurrent Bladder Cancer', The Journal of Urology, vol. 154, no. 2, pp. 379-384. https://doi.org/10.1016/S0022-5347(01)67054-X
Sarosdy, M. F. ; deVere White, Ralph W ; Soloway, M. S. ; Sheinfeld, J. ; Hudson, M. A. ; Schellhammer, P. F. ; Jarowenko, M. V. ; Adams, G. ; Blumenstein, B. A. / Results of a Multicenter Trial using the BTA Test to Monitor for and Diagnose Recurrent Bladder Cancer. In: The Journal of Urology. 1995 ; Vol. 154, No. 2. pp. 379-384.
@article{deaea22383c541529dc7c5451941cafe,
title = "Results of a Multicenter Trial using the BTA Test to Monitor for and Diagnose Recurrent Bladder Cancer",
abstract = "Objectives: We compare the Bard BTA† † Bainbridge Diagnotic Sciences, C.R. Bard, Inc., Redmond, WA. (bladder tumor antigen) test to voided cytology studies in patients undergoing surveillance cystoscopy for recurrent bladder cancer. Materials and Methods: A prospective, blinded, multicenter trial was performed. Results: A total of 499 patients underwent 1,014 cystoscopic examinations and tumor was identified in 151. The bladder tumor antigen test was mode sensitive than cytology studies in detecting recurrent cancer (p less than 0.001), being positive in 61 cases versus 25 for cytology. The trial in healthy volunteers and nonurological patients estimates bladder tumor antigen test specificity to be 95.9 percent. Conclusions: The bladder tumor antigen test is a simple, rapid and inexpensive adjunct to cystoscopy, and the results are equivalent or superior to those of voided cytology as performed in this trial.",
author = "Sarosdy, {M. F.} and {deVere White}, {Ralph W} and Soloway, {M. S.} and J. Sheinfeld and Hudson, {M. A.} and Schellhammer, {P. F.} and Jarowenko, {M. V.} and G. Adams and Blumenstein, {B. A.}",
year = "1995",
doi = "10.1016/S0022-5347(01)67054-X",
language = "English (US)",
volume = "154",
pages = "379--384",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Results of a Multicenter Trial using the BTA Test to Monitor for and Diagnose Recurrent Bladder Cancer

AU - Sarosdy, M. F.

AU - deVere White, Ralph W

AU - Soloway, M. S.

AU - Sheinfeld, J.

AU - Hudson, M. A.

AU - Schellhammer, P. F.

AU - Jarowenko, M. V.

AU - Adams, G.

AU - Blumenstein, B. A.

PY - 1995

Y1 - 1995

N2 - Objectives: We compare the Bard BTA† † Bainbridge Diagnotic Sciences, C.R. Bard, Inc., Redmond, WA. (bladder tumor antigen) test to voided cytology studies in patients undergoing surveillance cystoscopy for recurrent bladder cancer. Materials and Methods: A prospective, blinded, multicenter trial was performed. Results: A total of 499 patients underwent 1,014 cystoscopic examinations and tumor was identified in 151. The bladder tumor antigen test was mode sensitive than cytology studies in detecting recurrent cancer (p less than 0.001), being positive in 61 cases versus 25 for cytology. The trial in healthy volunteers and nonurological patients estimates bladder tumor antigen test specificity to be 95.9 percent. Conclusions: The bladder tumor antigen test is a simple, rapid and inexpensive adjunct to cystoscopy, and the results are equivalent or superior to those of voided cytology as performed in this trial.

AB - Objectives: We compare the Bard BTA† † Bainbridge Diagnotic Sciences, C.R. Bard, Inc., Redmond, WA. (bladder tumor antigen) test to voided cytology studies in patients undergoing surveillance cystoscopy for recurrent bladder cancer. Materials and Methods: A prospective, blinded, multicenter trial was performed. Results: A total of 499 patients underwent 1,014 cystoscopic examinations and tumor was identified in 151. The bladder tumor antigen test was mode sensitive than cytology studies in detecting recurrent cancer (p less than 0.001), being positive in 61 cases versus 25 for cytology. The trial in healthy volunteers and nonurological patients estimates bladder tumor antigen test specificity to be 95.9 percent. Conclusions: The bladder tumor antigen test is a simple, rapid and inexpensive adjunct to cystoscopy, and the results are equivalent or superior to those of voided cytology as performed in this trial.

UR - http://www.scopus.com/inward/record.url?scp=0029074615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029074615&partnerID=8YFLogxK

U2 - 10.1016/S0022-5347(01)67054-X

DO - 10.1016/S0022-5347(01)67054-X

M3 - Article

C2 - 7609102

AN - SCOPUS:0029074615

VL - 154

SP - 379

EP - 384

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 2

ER -